AngioDynamics Granted Patent for Laser Treatment Innovation.QUEENSBURY, N.Y. -- AngioDynamics (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ANGO ANGO Algemene Nederlandse Gehandicapten Organisatie (Dutch: Equal Opportunities for Persons with Disabilities) ), a leading provider of innovative medical devices used by interventional radiologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease Peripheral Vascular Disease Definition Peripheral vascular disease is a narrowing of blood vessels that restricts blood flow. It mostly occurs in the legs, but is sometimes seen in the arms. , announced today that the U.S. Patent and Trademark Office (USPTO USPTO abbr. United States Patent and Trademark Office ) has granted the Company Patent No. 7,273,478, entitled "Endovascular Treatment Device Having a Fiber Tip Spacer." This patent covers an endovascular laser treatment device with a spacer that positions the fiber tip away from the vessel wall, and for the method of using that device. AngioDynamics has additional related patent applications pending before the USPTO covering venous treatment devices and methods using advanced non-contact technology designed to further enhance treatment outcomes after laser surgery. "This patent is an important addition to our growing intellectual property portfolio covering the treatment of venous disease using non-contact devices to minimize patient discomfort and bruising," commented Eamonn Hobbs, AngioDynamics President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . "Innovation is a hallmark of AngioDynamics, and as a recognized leader in the treatment of venous disease we are always looking to enhance our product portfolio, especially when it comes to improving the patient's experience. We are continuing to develop this portfolio and look forward to further, solid intellectual property in this area." About AngioDynamics AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, surgeons, and other physicians for the minimally invasive treatment of cancer and peripheral vascular disease. The Company's diverse product line includes market-leading radiofrequency ablation Radiofrequency ablation (RFA) A technique for removing a tumor by heating it with a radiofrequency current passed through a needle electrode. Mentioned in: Liver Cancer, Prenatal Surgery systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic thrombolytic /throm·bo·lyt·ic/ (throm?bo-lit´ik) dissolving or splitting up a thrombus, or an agent that so acts. thrombolytic 1. dissolving or splitting up a thrombus. 2. an agent that dissolves or splits up a thrombus. products, embolization embolization /em·bo·li·za·tion/ (em?bo-li-za´shun) 1. the process or condition of becoming an embolus. 2. therapeutic introduction of a substance into a vessel in order to occlude it. products and venous products. About Forward-Looking Statements The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended June 2, 2007, may affect the actual results achieved by the Company. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion